Product Image

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best
4.7
★ ★ ★ ★ ★
(1086 ratings)
Niacin 500 mg
Product Image
Score82
A clearly labeled sustained-release nicotinic acid product with strong cardiovascular alignment. The large amount requires more monitoring than ordinary vitamin supplementation.
How scoring works
Quantity:120 Tablet(s) • (120 servings)
Goals:
Cardiovascular Support
Heart Health

Score 82

A clearly labeled sustained-release nicotinic acid product with strong cardiovascular alignment. The large amount requires more monitoring than ordinary vitamin supplementation.
How scoring works
$17.99($0.14 per serving)
iHerb
$ 17.99
iHerb
$ 17.99
Walmart
$ 19.43
Vitacost
$ 19.19
Pure Formulas
$ 28.56
Report prices

Analysis

The chemical form and sustained-release design are both clear, making the product easier to judge than generic high-dose niacin. Nicotinic acid is the form most relevant to lipid-focused use.

The large amount is not intended for basic vitamin B3 coverage. Sustained release may spread exposure over time, but it does not remove dose-related risks and may increase concern about liver tolerance.

Its strongest fit is a professionally supervised cardiovascular plan when nicotinic acid is specifically appropriate. Skin support is a secondary nutritional use and does not justify this amount on its own.

Who is it for
  • Adults using nicotinic acid under professional guidance
  • People who need a sustained-release format
  • Users with a defined lipid-focused plan
Best for
  • Clinician-guided nicotinic acid use
  • Sustained-release niacin routines
  • High-dose vitamin B3 plans

Pros

  • Clearly identifies nicotinic acid
  • Sustained-release delivery
  • Strong serving value

Cons

  • Too strong for routine nutrition
  • Still carries dose-related risks
  • Not justified for skin support alone

Warnings

  • Sustained-release nicotinic acid can affect liver enzymes and should not be used casually at this amount.
  • The dose may raise blood glucose or uric acid, which matters for diabetes or gout.
  • Flushing, dizziness, and stomach upset may still occur despite the sustained-release design.

Nutrient quality

85 Highest impact

Sustained-release nicotinic acid provides a purposeful cardiovascular niacin form. The amount is meaningful for targeted cardiovascular use.

.

Ingredient transparency

84 Highest impact

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.

Customer satisfaction

70 High impact

The aggregate satisfaction measure is strong and supported by adequate volume. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.

Value for money

89 Highest impact

The price is reasonable for the formula quality and dose. Each serving provides good cost efficiency.

.
Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
Highest effect
A- Goal FitA- Strength of SupportD+ CoverageA+ Formula Quality
Niacin · 500 mg

Nicotinic acid has a direct and well-established effect on blood lipids, giving the formula strong cardiovascular relevance. The 500 mg sustained-release amount is a pharmacologically meaningful dose rather than a routine nutritional serving.

Controlled release may reduce rapid flushing, but it does not remove the risks associated with high-dose niacin. Sustained-release nicotinic acid may cause flushing and raise liver enzymes, so ongoing use warrants clinician-supervised liver and metabolic monitoring.

Study evidence
Niacin Supportive 136 studies
Heart Health
Heart Health
Impact
High effect
B- Goal FitB Strength of SupportD+ CoverageA Formula Quality

Nicotinic acid can materially change lipid levels, making the formula relevant in selected medically supervised situations. The sustained-release 500 mg dose is not a general wellness option and has not consistently improved cardiovascular outcomes when added to modern treatment.

The single-active design is transparent and focused on lipid management rather than broad heart support. Sustained-release niacin can raise liver enzymes, blood sugar, and uric acid, so the 500 mg dose calls for clinical monitoring rather than unsupervised use.

Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per serving
Niacin (Nicotinic Acid)
 500 mg
Gluten Free Adults 18–50 Vegan Vegetarian
Report overview
Niacin (Nicotinic Acid) · 500 mg OverallScore84
A+ Active Ingredient Quality & BioavailabilityB+ Dose, Safety & Label TransparencyC Value

Sustained-release nicotinic acid is strongly aligned with cardiovascular use and provides an established amount. The controlled-release design may moderate rapid exposure, but the supplied label data does not include a niacin-flush warning. Its serving cost offers reasonable value for a specialized-release product.

View ingredientView products
Loading alternative details
80 Performance

Niacin (Vitamin B3) 500 mg

Solgar
<p>Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.</p>
79 Performance

Niacin-Time 500 mg

Carlson
<p>Timed-release nicotinic acid provides a transparent cardiovascular-focused dose in a long-supply format. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, controlled delivery does not remove flushing or liver-related concerns from high-dose niacin.</p>
82 Performance

No Flush Niacin (Inositol Hexanicotinate) 800 mg

Life Extension
<p>Clearly named inositol hexanicotinate provides substantial flush-free niacin exposure with economical serving value. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, its cardiovascular effects may be less direct and reliable than those of nicotinic acid.</p>
86 Budget

Niacinamide B-3 100 mg

Source Naturals
<p>A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.</p>
82 Budget

Niacin 100 mg

Nature's Way
<p>Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. Serving cost is lower than the original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.</p>
82 Budget

Niacin 100 mg

Bluebonnet
<p>Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. Serving cost is lower than the original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.</p>
80 Value

Niacin 50 mg

Carlson
<p>A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its lower serving cost and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.</p>
85 Value

Niacin 100 mg

Source Naturals
<p>A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its lower serving cost and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.</p>
80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar
<p>Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  8. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  9. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  10. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  11. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  12. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  13. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  14. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  15. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  16. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin